Indivior to Merge with Supernus in All-Stock Deal, Raises 2026 Guidance
INDV has more than doubled off its 52-week low of $19.31.
Summary
Indivior announced an all-stock merger with Supernus Pharmaceuticals, exchanging 1.5401 Indivior shares for each Supernus share, resulting in a combined company with Indivior shareholders owning ~56.5% and Supernus ~43.5%. The deal, targeted to close in Q4 2026, combines complementary CNS portfolios and follows Indivior's raised 2026 guidance earlier today, which now projects SUBLOCADE revenue up ~20% year-over-year and adjusted EBITDA up ~68% at the midpoint. The merger creates a larger, more diversified CNS-focused entity, potentially enhancing pipeline and commercial scale. The guidance raise, driven by strong SUBLOCADE growth, reinforces the standalone momentum. Watch for integration details and regulatory approvals as the closing approaches.
At the time of this announcement, INDV was trading at $42.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $19.31 to $42.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.